Promising Medical Stocks To Follow Today - November 8th

Key Points

• Stryker, Humana, and Gilead Sciences were highlighted as medical stocks to watch after ranking among the sector’s highest in recent dollar trading volume.
• Stryker shares fell $9.81 to $325.26 on Friday, while Humana gained $20.90 to $432.69.
• Gilead Sciences shares slipped $0.68 to $166.89; its trading volume was about 5.8 million shares, below its 7.1 million average.

Stryker, Humana, and Gilead Sciences are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of companies involved in healthcare, such as pharmaceutical and biotech firms, medical-device makers, and healthcare providers. Investors may group them as a sector because their performance can be influenced by factors like medical innovation, regulation, and healthcare demand. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

Stryker (SYK)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

NYSE SYK traded down $9.81 during trading hours on Friday, reaching $325.26. The company's stock had a trading volume of 3,778,566 shares, compared to its average volume of 3,039,953. The firm has a fifty day simple moving average of $292.37 and a 200-day simple moving average of $323.59. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30. Stryker has a 52 week low of $267.00 and a 52 week high of $389.33. The stock has a market cap of $123.83 billion, a P/E ratio of 34.64, a P/E/G ratio of 2.24 and a beta of 0.78.

Read Our Latest Research Report on SYK

Humana (HUM)

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

HUM traded up $20.90 during trading on Friday, reaching $432.69. 2,576,136 shares of the company's stock were exchanged, compared to its average volume of 1,525,266. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. Humana has a one year low of $163.11 and a one year high of $456.50. The firm has a fifty day moving average price of $403.96 and a two-hundred day moving average price of $312.27. The stock has a market capitalization of $51.96 billion, a PE ratio of 42.09, a price-to-earnings-growth ratio of 2.67 and a beta of 0.65.

Read Our Latest Research Report on HUM

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

GILD traded down $0.68 during midday trading on Friday, hitting $166.89. 5,817,414 shares of the company were exchanged, compared to its average volume of 7,121,156. The firm's 50 day moving average price is $153.04 and its 200-day moving average price is $140.94. The company has a quick ratio of 0.95, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. The firm has a market capitalization of $207.00 billion, a P/E ratio of -52.81 and a beta of 0.35. Gilead Sciences has a 1-year low of $116.88 and a 1-year high of $176.58.

Read Our Latest Research Report on GILD

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.